We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $962M
1-Year Est. Return 524.64%
This Fund
S&P 500
This Quarter Est. Return
+1.21%
1 Year Est. Return
+524.64%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.08%
10 Year Est. Return
–
AUM
$224M
AUM Growth
+$40.9M
Cap. Flow
+$15.5M
Cap. Flow %
6.91%
Top 10 Hldgs %
33.66%
Holding
127
New
36
Increased
38
Reduced
22
Closed
31

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$5.26M
2
MGNX icon
MacroGenics
MGNX
+$5.18M
3
ELOX
Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
+$3.94M
4
VCYT icon
Veracyte
VCYT
+$3.89M
5
MSAC
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
+$3.65M

Top Sells

Rank Stock Value
1
VCEL icon
Vericel Corp
VCEL
+$6.78M
2
CRIS icon
Curis
CRIS
+$4.17M
3
MSACU
Medicus Sciences Acquisition Corp. Unit
MSACU
+$4.01M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$3.36M
5
LRMR icon
Larimar Therapeutics
LRMR
+$2.8M

Sector Composition

Rank Sector Weight
1 Healthcare 84.58%
2 Miscellaneous 8.64%
3 Financials 6.1%
4 Industrials 0.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
CALL
State Street SPDR S&P Biotech ETF
XBI
$11.3B
$12.8M 5.7%
+94,400
New +$12.4M
KDNY
2
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$12.8M 5.7%
+14,158
New +$226K
DRNA
3
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$8.58M 3.83%
229,892
+29,892
+15% +$916K
MRUS
4
DELISTED
Merus
MRUS
$6.76M 3.01%
320,815
+76,102
+31% +$1.68M
MRTX
5
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$6.1M 2.72%
37,753
+32,753
+655% +$5.26M
VCYT icon
6
Veracyte
VCYT
$3.41B
$6.03M 2.69%
150,861
+90,861
+151% +$3.89M
MORF
7
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$5.96M 2.66%
103,858
+43,858
+73% +$2.41M
AMYT
8
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$5.54M 2.47%
456,537
+26,674
+6% +$331K
BHVN
9
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$5.5M 2.45%
56,626
+6,537
+13% +$531K
IMGN
10
DELISTED
Immunogen Inc
IMGN
$5.45M 2.43%
827,587
+98,223
+13% +$685K
INSM icon
11
Insmed
INSM
$27.3B
$5.05M 2.25%
177,433
-13,377
-7% -$397K
RACB
12
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
$5.03M 2.24%
495,855
-4,145
-0.8% -$43.7K
MGNX icon
13
MacroGenics
MGNX
$275M
$4.75M 2.12%
+176,915
New +$5.18M
HZNP
14
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$4.68M 2.09%
50,035
+1,559
+3% +$143K
ITCI
15
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$4.62M 2.06%
113,258
-16,859
-13% -$623K
VSTM icon
16
Verastem
VSTM
$732M
$4.27M 1.9%
87,446
-12,345
-12% -$515K
RNLX
17
DELISTED
Renalytix plc American Depositary Shares
RNLX
$3.89M 1.74%
126,145
-8,410
-6% -$252K
ELOX
18
DELISTED
Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
$3.76M 1.68%
+47,188
New +$3.94M
MSAC
19
DELISTED
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
$3.6M 1.61%
+373,275
New +$3.65M
IMTX icon
20
Immatics
IMTX
$1.44B
$3.36M 1.5%
289,408
+247,611
+592% +$2.91M
ACRS icon
21
Aclaris Therapeutics
ACRS
$892M
$3.31M 1.48%
188,719
-148,018
-44% -$3.36M
TCRR
22
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$3.09M 1.38%
188,142
+32,997
+21% +$667K
HALO icon
23
Halozyme
HALO
$12.3B
$3.03M 1.35%
66,673
-38,272
-36% -$1.69M
STXS icon
24
Stereotaxis
STXS
$130M
$2.95M 1.32%
+306,404
New +$2.42M
CLDX icon
25
Celldex Therapeutics
CLDX
$3.07B
$2.93M 1.31%
+9,921
New +$272K
1
2 3 4 5

Similar funds

LGP
Leonard Green & Partners Los Angeles, California $962M AUM 35.11% 1-Year Est. Return
PL
Parthenon LLC Louisville, Kentucky $962M AUM 27.46% 1-Year Est. Return
LAM
L2 Asset Management Wayland, Massachusetts $963M AUM 38.06% 1-Year Est. Return
ACP
Aviance Capital Partners Naples, Florida $963M AUM 32.56% 1-Year Est. Return
GIG
Goodnow Investment Group Darien, Connecticut $964M AUM 2.51% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
BEAM
Baker Ellis Asset Management Vancouver, Washington $964M AUM 39.24% 1-Year Est. Return
RAM
Ramirez Asset Management New York $960M AUM 30.25% 1-Year Est. Return

Silverarc Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, Silverarc Capital Management held 127 positions worth $224M, up 22% from $183M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Silverarc Capital Management deployed $15.5M of net new capital in Q2 2021, opening 36 new positions and adding to 38 existing holdings. Its largest new stake was MacroGenics: 176,915 shares worth $4.75M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 91% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Curis, an estimated $4.17M trimmed.

  • Silverarc Capital Management's largest Q2 2021 buy was MacroGenics: 176,915 shares worth $4.75M.
  • Silverarc Capital Management added most to Mirati Therapeutics, Inc. Common Stock in Q2 2021, an estimated $5.26M increase.
  • Silverarc Capital Management's biggest Q2 2021 reduction was Curis, cutting an estimated $4.17M.
  • Silverarc Capital Management fully exited Vericel Corp in Q2 2021, selling an estimated $6.78M.
  • Silverarc Capital Management's ten largest holdings make up 34% of its $224M portfolio in Q2 2021.
  • Silverarc Capital Management opened 36 new positions and closed 31 in Q2 2021.
  • Silverarc Capital Management's portfolio value rose 22% quarter-over-quarter to $224M.

Based on Silverarc Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.